Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Objective: This study systematically reviews health economic evaluations of influenza vaccines in China and synthesizes the evidence on different vaccine categories.
Methods: We searched databases, including the China Hospital Knowledge Database, Wanfang, PubMed, Web of Science, and Embase, for studies on the health economics of influenza vaccines in China from 2015 to 2024. Studies were selected based on predefined criteria, and relevant data were extracted for analysis. The research utilized a parameter, ICER/threshold, defined as the ICER divided by the GDP per capita, to compare the results of cost-effectiveness analysis (CEA) studies.
Results: A total of 1743 articles were identified, of which 25 met the inclusion criteria for full-text review. These included 19 Chinese studies and 6 English studies. Study populations were predominantly older adults (52.0%), followed by children, adolescents, people with chronic disease, and pregnant women. Vaccination strategies included trivalent inactivated influenza vaccine (TIV), quadrivalent inactivated influenza vaccine (QIV), trivalent live-attenuated influenza vaccine (LAIV), and non-vaccination groups. For TIV, 94.7% reported positive cost-effectiveness or cost-benefit results, with 21.1% identifying it as the most dominant strategy. For QIV, six studies compared it with a non-vaccinated group, and five (83.3%) reported favorable economic results. The study on LAIV showed cost-effectiveness compared to no vaccination, but not compared to QIV. The ICER threshold for TIV is the most favorable, and the population that exhibits the highest cost-effectiveness and benefit from vaccination is those people with underlying health conditions.
Conclusions: TIV vaccination is often cost-effective, especially for people with chronic diseases, children, and older adults. Prioritizing TIV vaccination for those people with chronic diseases is recommended.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11946278 | PMC |
| http://dx.doi.org/10.3390/vaccines13030332 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Influenza Vaccine Effectiveness During the 2023/2024 Season: A Test-Negative Case-Control Study Among Emergency Hospital Admissions With Respiratory Conditions in Northern Ireland.
Influenza Other Respir Viruses
September 2025
Public Health Agency, Belfast, UK.
Background: We evaluated the effectiveness of the influenza vaccine programme against infection among emergency hospital admissions with respiratory conditions in Northern Ireland during the 2023/2024 influenza season.
Methods: Using a test-negative design, we compared the odds of vaccination between patients who tested positive (cases) and negative (controls) for laboratory-confirmed influenza, adjusting for confounders. VE was stratified by age group, sex and time since vaccination.
Pulmonary delivery of small circular RNA vaccines for influenza prevention.
J Control Release
September 2025
Department of Pharmaceutical Sciences, College of Pharmacy, University of Michigan, Ann Arbor, MI 48109, USA; Bioinnovations in Brain Cancer, Biointerfaces Institute; The Developmental Therapeutics Program, Rogel Cancer Center; Center for RNA Biomedicine, University of Michigan, Ann Arbor, MI 48109,
Lipid nanoparticles (LNPs) have played an instrumental role in the delivery of RNA therapeutics and vaccines, including the emerging class of synthetic circular RNA (circRNA). Pulmonary vaccines hold the potential to prevent various respiratory infectious diseases, such as influenza caused by influenza infection. Here, we report the pulmonary delivery of LNPs loaded with highly stable small circRNA vaccine for influenza prevention.
View Article and Find Full Text PDFCaregivers' attitudes toward school-based vaccination programs: A comparison of COVID-19, HPV, influenza, and dengue vaccines in Brazil.
Vaccine
September 2025
Department of Epidemiology, Institute of Social Medicine, University of State of the Rio de Janeiro. 524 São Francisco Xavier St. Maracanã, Bloco E, 7th Floor, Rio de Janeiro - RJ, Cep 20550-013, Brazil. Electronic address:
Background: There is limited data on adult opinions toward school-based vaccination programs, which can supplement clinic-based strategies in the Brazilian public health system. Since 2016, vaccination rates among Brazilian children and adolescents have shown worrisome declines, remaining well below full coverage, including for more recently introduced COVID-19 vaccines. School vaccination programs are not commonly implemented or monitored in Brazil.
View Article and Find Full Text PDFExamining the contributions of demographic variables to vaccination uptake among the U.S. aged 50.
Vaccine
September 2025
AgeLab, Massachusetts Institute of Technology, 77 Massachusetts Avenue, E40-275K, Cambridge, MA 02139, United States.
Vaccine uptake for five conditions harmful to older adults (seasonal influenza, pneumococcus infections, shingles, Covid-19, and pertussis) falls short of universal coverage, and discrepancies further emerge by gender, race, and vaccine target. Drawing on a cross-sectional nationally representative survey of 2623 U.S.
View Article and Find Full Text PDFThe Role of Enoxaparin in Influenza Virus Infections and Its Therapeutic Implications.
J Infect Dis
September 2025
University of Veterinary Medicine Vienna, Infectiology, Vienna, Austria.
Frequent emergence of respiratory viruses with pandemic potential, like SARS-CoV-2 or influenza, underscores the need for broad-spectrum prophylaxis. Existing vaccines show reduced efficacy against newly emerged variants, and the ongoing risk of new outbreaks highlights the importance of alternative strategies to prevent infection and viral transmission. As respiratory viruses primarily enter through the nose, formulations targeting the nasal epithelium are attractive candidates to neutralize pathogens and thus prevent or minimize infection.
View Article and Find Full Text PDF